|
|
|
|
|
Last Trade
|
Last Trade:
$1.14
|
Change:
-0.10 (-8.07%)
|
Trade Time:
Aug 08
|
Market Cap:
$29.78M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biotechnology company focused on the research and discovery of new and
effective treatments for psychiatric and neurological disorders. Epidemiological
data indicate neuropsychiatric disorders as being some of the most prevalent,
devastating, and yet poorly treated illnesses.
Our biotech operations focus on developing drugs that target the pathophysiology
underlying such disorders rather than symptomatic treatments, with the goal of
developing new pharmacological agents that display significant advantages over
conventional therapies with respect to efficacy and tolerability. We
particularly focus on the cross-talk between the immune system and brain
disorders and how immune dysregulation affects CNS function.
For many years the brain was considered an "immune-privileged" organ.
|
|
|
|